GastroEsophageal Cancer New Reference: Trastuzumab Deruxtecan for her2+ Gastric Cancer Ulas D. Bayraktar, MD 2025-06-02
Non-Small Cell Lung Cancer New Reference: Taletrectinib for ROS1+ NSCLC Ulas D. Bayraktar, MD 2025-06-02
Hepatocellular Carcinoma New Indication: Ipilimumab/Nivolumab for Unresectable HCC Ulas D. Bayraktar, MD 2025-06-02
Breast Cancer New Reference: Inavolisib with Palbociclib and Fulvestrant for Advanced ER+ Breast Cancer Ulas D. Bayraktar, MD 2025-06-02
Prostate Cancer New Reference: Enzalutamide with Radium-223 for Prostate Cancer Ulas D. Bayraktar, MD 2025-06-02
Bladder Cancer New Indication: Neoadjuvant Durvalumab with CISplatin/Gemcitabine for Upper GU Tract Cancer Ulas D. Bayraktar, MD 2025-05-05
Breast Cancer New Protocol: Neoadj Pembrolizumab + TP for her2+ Breast Cancer Ulas D. Bayraktar, MD 2025-05-05
Colorectal Cancer New Reference: Neoadjuvant FOLFOX + Panitumumab for Colon Cancer Ulas D. Bayraktar, MD 2025-05-05
Follicular Lymphoma New Reference: RiTUXimab alone for Follicular Lymphoma Ulas D. Bayraktar, MD 2025-05-05
